.jpeg)
2026-05-15 02:57:37
The FDA has granted approval to Teclistamab (Tecvayli) in combination with Daratumumab and hyaluronidase (Darzalex Faspro) for relapsed or refractory multiple myeloma (RRMM). Based on pivotal MajesTEC-3 data, this dual-targeted immunotherapy demonstrates transformative PFS and OS benefits, offering a new standard for heavily pretreated patients. This article dissects the mechanism, trial outcomes, safety profile, and clinical implications, providing actionable insights for global oncology teams.
2026-05-12 02:17:51
Venetoclax, a BCL-2 inhibitor, demonstrates remarkable efficacy in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and acute myeloid leukemia (AML). However, its potency necessitates stringent safety protocols, particularly in managing tumor lysis syndrome (TLS), neutropenia, infections, and pregnancy risks. This article unpacks monitoring strategies and risk mitigation practices from global clinical guidelines to optimize treatment outcomes.
2026-04-29 06:05:15
Plerixafor is a hematopoietic stem cell mobilizer used in combination with granulocyte colony-stimulating factor (G-CSF) for hematopoietic stem cell collection and autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma. This article provides detailed information on various side effects of plerixafor, including serious adverse reactions requiring immediate medical attention, common mild to moderate reactions, and systematic side effect management protocols for healthcare professionals.
2026-04-21 02:57:14
Lusutrombopag is an oral small-molecule thrombopoietin receptor agonist approved by the U.S. FDA in 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. This article details its core mechanism of action, standard dosage regimen, and proper drug storage requirements.
2026-04-13 07:05:12
Anagrelide is a platelet-lowering agent used in essential thrombocythemia (ET). Learn about its indications, mechanism, potential side effects, and expert guidance for safe use in managing elevated platelet counts.
2026-04-13 04:04:58
A comprehensive overview of Azacitidine (Azacitidine) for Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Chronic Myelomonocytic Leukemia (CMML). Learn about indications, legal purchase options, and essential precautions for patients seeking cross-border medication access.
2026-04-07 03:22:33
The clinical medication regimen of Avatrombopag (brand name Doptelet) 20mg specification, details the initial dose, adjustment rules and personalized medication principles for immune thrombocytopenia and chronic liver disease-related thrombocytopenia, to provide professional reference for clinical safe medication.
2026-04-07 02:55:19
This article explains the core pharmacological mechanism of Gilteritinib (brand name Xospata) in the treatment of FLT3-mutated acute myeloid leukemia (AML), and sorts out the relevant impacts of drug discontinuation on disease control and clinical outcomes, to provide professional reference for clinical medication decision-making.
2026-04-03 07:03:54
Avatrombopag (brand name Doptelet) and Hetrombopag are both oral thrombopoietin (TPO) receptor agonists, core treatments for thrombocytopenia. While sharing a homologous mechanism of action, they have clear differences in molecular structure, global indication coverage, clinical application scenarios, and pharmacokinetic profiles. This article explains their key distinctions and clinical selection logic.
2026-04-01 02:55:09
On April 1, 2026, the U.S. FDA granted accelerated approval to Kresladi (marnetegragene autotemcel), the first gene therapy for severe leukocyte adhesion deficiency type I (LAD-I), indicated for pediatric patients with biallelic ITGB2 variants and no available HLA-matched sibling donor for allogeneic hematopoietic stem cell transplantation.
2026-03-24 04:27:54
Pegcetacoplan is a complement C3 inhibitor for paroxysmal nocturnal hemoglobinuria (PNH) treatment. This article details injection reactions, infection risks and monitoring points to help patients use medication safely.
2026-03-20 03:20:58
Pegcetacoplan is a PEGylated complement C3 inhibitor used for treating adult paroxysmal nocturnal hemoglobinuria, providing comprehensive control of complement-mediated hemolytic reactions.
